skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Datamonitor Healthcare uses a patient-based approach to size the commercial potential of Alzheimer’s disease across the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK) from 2012 to 2021.

Alzheimer’s disease across the US, Japan, and five major EU markets is set to double in value over the next 10 years. The catalysts for this growth include an increasingly elderly population, earlier and improved diagnosis, and the introduction of new therapeutic classes.

Pfizer/Eisai’s Aricept, formerly the highest selling brand in the market, has been overtaken by Forest/Lundbeck/Merz’s Namenda (memantine). The two drugs are following differing growth trajectories: Namenda’s sales will continue to rise while Aricept’s revenues are severely eroded by generic competition.

The beta amyloid immunotherapy solanezumab has the potential to grow the market by $4.6bn. Datamonitor Healthcare forecasts that around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021 in the US, Japan, and the five major EU markets.

Patient-based forecasting methodology utilizing epidemiology data and primary research with 133 neurologists across the US, Japan, and five major EU markets. Pricing, dosing, and future event assumptions are added to create Datamonitor Healthcare’s forecast.


This is an Alzheimer’s Disease analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.


  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート



    Topics Coronavirus Vaccines

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...


    By Dustin Phan


    Topics Coronavirus Clinical Trials

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.